Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by Wall Street Zen

Posted by Stanley Muller on Aug 10th, 2026

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Other research analysts have also issued reports about the company. Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. HC Wainwright lowered their price objective on shares of Heron Therapeutics to $2.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Heron Therapeutics currently has a consensus rating of “Hold” and an average price target of $2.00.

Check Out Our Latest Analysis on Heron Therapeutics

Heron Therapeutics Price Performance

HRTX opened at $0.49 on Friday. The company has a debt-to-equity ratio of 17.51, a current ratio of 2.53 and a quick ratio of 1.51. The stock has a market capitalization of $92.90 million, a price-to-earnings ratio of -2.73 and a beta of 1.65. The business has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.84. Heron Therapeutics has a 12 month low of $0.38 and a 12 month high of $1.57.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million for the quarter, compared to analysts’ expectations of $36.72 million. On average, research analysts expect that Heron Therapeutics will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Several large investors have recently added to or reduced their stakes in HRTX. BlackRock Inc. bought a new stake in Heron Therapeutics in the second quarter valued at $4,503,000. Deutsche Bank AG bought a new stake in shares of Heron Therapeutics during the second quarter valued at approximately $41,000. Persistent Asset Partners Ltd acquired a new position in Heron Therapeutics during the 2nd quarter worth $50,000. Bank of New York Mellon Corp acquired a new position in Heron Therapeutics during the 2nd quarter worth $169,000. Finally, GSA Capital Partners LLP bought a new position in shares of Heron Therapeutics in the second quarter worth $445,000. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

(Get Free Report)

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.